MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

A Washington State University Spokane research team has made a breakthrough at the cellular level in studying the secrets of ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to aggressive ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic ... We took advantage of the hGx model to interrogate the origins of infant acute myeloid leukemia ...

The chimeric BCR–ABL oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML ... and LMB also preferentially eliminates mouse bone marrow cells that express BCR–ABL.

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

DeepSeek uses an approach called test-time or inference-time compute, which slices queries into smaller tasks, turning each into a new prompt that the model tackles. Each step requires running a ...